

<input type="checkbox"/> New to Therapy
<input type="checkbox"/> Current Therapy

Customer Information

Customer Name: _____
 Date of Birth: _____ Gender: Male or Female
 Address: _____
 City: _____ State: _____ Zip: _____
 Home Phone: _____ Work Phone: _____
 Cell Phone: _____ E-mail: _____
Please attach copy of front and back of customer's insurance card(s)
 Insurance Company Name: _____
 Insurance Company Phone: _____
 Policy holder: _____
 Policy holder Employer: _____
 Relationship to Customer: _____
 ID# _____ Group# _____
 RxBIN: _____ RxPCN: _____

Prescriber Information

Practice/ Organization Name: _____
 Physician Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone#: _____ Fax#: _____
 DEA# _____ NPI# _____
 License#: _____ Medicaid UPIN#: _____
 Physician Specialty: _____
Date Shipment Needed: _____
Ship to: Patient Prescriber Infusion Clinic
 Shipment Address: _____
 Attn: _____
 City: _____ State: _____ Zip: _____
If shipped to the physician's office, physician accepts on behalf of patient for administration in office.

Clinical Information and Prescription

Diagnosis and Clinical Information:
 M06.9 Rheumatoid Arthritis M45.9 Ankylosing Spondylitis L40.59 Psoriatic Arthritis
 M08.01 Juvenile chronic polyarthritis Other: _____
 Date of Diagnosis or Years with Disease: _____ Patients Allergies: _____
 Patient Weight: _____ kg / lbs Patient Height: _____ cm / in
 Has the patient had a NEGATIVE tuberculin skin test? Yes No
 Is the patient a carrier of the Hepatitis B virus? Yes No Latex allergy: Yes No
 Prior DMARD's and length of treatment: _____
 Expected First Dose Date: _____ Injection training needed: Yes No

Actemra® (tocilizumab) 162 mg SC syringe 162 mg SC ACTPen 20mg/ml IV vial (patient weight needed)
 Inject 162 mg SC once weekly (>= 100 kg) OR every other week (<100 kg) Infuse _____ mg/kg IV every 4 weeks as directed

Cimzia® (certolizumab pegol)
 Initial Dose: 400mg SC @ 0, 2, 4 weeks prefilled syringe OR 400mg SC @ 0, 2, 4 weeks lyophilized powder vial (in office)
 Maintenance Dose: 400mg SC every 4 weeks 200mg SC every 2 weeks Prefilled Syringe Vial

Enbrel® (etanercept) Dose: 50mg SureClick 50mg Prefilled Syringe 25mg Prefilled Syringe 25mg Vial
 Dispense: Inject SC once per week Inject SC twice per week (JIA) inject 0.8mg/kg, max 50mg/week

Humira® (adalimumab) Dose: 40mg Pen Auto Injector 40mg Prefilled Syringe Citrate/buffer free formulation
 20 mg Prefilled Syringe 10mg Prefilled Syringe
 Dispense: Inject SC once every other week Inject SC once per week Other:

Kezvara® (sarilumab) Inject SC once every 2 weeks Prefilled Syringe OR Prefilled Pen
 Dose: 150mg/1.14ml 200mg/1.14ml

Olumiant® (baricitinib) 2 mg PO once daily

Orencia® (abatacept) Inject 125mg Prefilled Syringe SC once weekly
 Infuse IV over 30 minutes every 2 weeks for 3 doses. Starting at week 8, infuse over 30 minutes every 4 weeks
 500mg (pat. <60kg) 750mg (60-100kg) 1000mg (>100kg) 10mg/kg if less than 75kg (JA)

Remicade® (infliximab) OR **Inflectra®** OR **Renflexis®** Infuse IV over 2 hours as directed
 Dose: 3mg/kg @ 0, 2, 6 weeks 3mg/kg every 8 weeks 5mg/kg @ 0, 2, 6 weeks then every 6 weeks thereafter (Ankyl Spon.)
 10mg/kg @ 0, 2, 6 weeks then every 6 weeks thereafter Other dosing:

Rinvoq® (upadacitinib) 15 mg PO once daily

Rituxan® (rituximab) Infuse 1000mg IV bolus on day 1 and 15 every 6 months.

Simponi® (golimumab) Inject SC once per month **Simponi Aria®** (golimumab)
 50mg SmartJect™ OR 50mg prefilled syringe Infuse 2 mg/kg IV over 30 minutes; repeat dose at week 4 and then every 8 weeks thereafter

Xeljanz® (tofacitinib) 5 mg PO twice daily **Xeljanz XR®** (tofacitinib) 11 mg PO once daily

Quantity Prescribed: QS 30 days Other: _____ **Refills Authorized:** 0 1 2 3 6 1 yr Other: _____

Physician Signature (no stamps): _____ **Date:** _____

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.